Comparison engine · up to 4 candidates

Compare side-by-side.

Pick up to four peptides. We line up evidence tier, mechanism, half-life, routes, and contraindications. Human data first — never hype.

SemaxSelankDihexaCerebrolysin

Dimension	Semax	Selank	Dihexa PNB-0408	Cerebrolysin
Evidence tier	BHuman observational	BHuman observational	CPreclinical only	AHuman RCT evidence
Intelligence Score™	5.1/ 10 · Emerging	5.1/ 10 · Emerging	3.7/ 10 · Emerging	6.3/ 10 · Moderate
Family	ACTH(4-10) analogue	Tuftsin analogue (anxiolytic)	Angiotensin IV analogue	Porcine brain peptide complex
Half-life	Short	Short	Unknown (human)	Variable
Typical dose	200–600 mcg, 1–3× daily	250–500 mcg, 1–3× daily	Experimental	5–30 mL/day IV (clinical)
Routes	Intranasal	Intranasal, Subcutaneous	Oral, Topical (experimental)	Intravenous, Intramuscular
Tier label	Human observational	Human observational	Preclinical only	Human RCT
Mechanism	Modulates BDNF, dopamine, and serotonin systems; neuroprotective in stroke models.	Modulates GABA system and serotonin turnover; immunomodulatory.	HGF/c-Met signal augmentation in preclinical models.	Mixed neurotrophic and neuromodulatory effects.
Reported uses	—	—	—	—
Contraindications	— Pregnancy	— Pregnancy	— Active malignancy (theoretical, c-Met) — No human safety data	— Epilepsy (caution) — Severe renal impairment
Citations	1	1	1	1

BHuman observational

Intelligence Score™: 5.1/ 10 · Emerging
Family: ACTH(4-10) analogue
Half-life: Short
Typical dose: 200–600 mcg, 1–3× daily
Routes: Intranasal
Tier label: Human observational
Mechanism: Modulates BDNF, dopamine, and serotonin systems; neuroprotective in stroke models.
Reported uses: —
Contraindications: — Pregnancy
Citations: 1

BHuman observational

CPreclinical only

Intelligence Score™: 3.7/ 10 · Emerging
Family: Angiotensin IV analogue
Half-life: Unknown (human)
Typical dose: Experimental
Routes: Oral, Topical (experimental)
Tier label: Preclinical only
Mechanism: HGF/c-Met signal augmentation in preclinical models.
Reported uses: —
Contraindications: — Active malignancy (theoretical, c-Met)
— No human safety data
Citations: 1

AHuman RCT evidence

Plain-English summary

Summarize this comparison — evidence depth, mechanism overlap, and the strongest unknowns.

Suggestive, never prescriptive. Discuss with a clinician. How we grade evidence.